Open Letter to G7 Heads of State on Neglected Tropical Diseases

To: Prime Minister Shinzō Abe; Prime Minister David Cameron; Prime Minister Stephen Harper; President François Hollande; Chancellor Angela Merkel; President Barack Obama; Prime Minister Matteo Renzi

Cc: G7 Foreign Ministers and G7 Sherpas

March 3, 2015

Your Excellencies:

Ahead of the 2015 G7 Summit, we would like to applaud G7 leaders for putting global health, particularly neglected and poverty-related diseases, at the forefront of the G7's development agenda this year.

Together, we represent a group of experts, advocates, researchers and implementing partners from public and private sector organizations that share a vision of a world free of neglected tropical diseases (NTDs).¹ Our work is underpinned by the landmark 2012 London Declaration on NTDs, which captures our commitment to accelerate progress towards the World Health Organization's (WHO) 2020 control and elimination targets. We are writing to urge you to sustain current funding levels for NTD control and elimination efforts, and implement a collective plan of action to fill the remaining gaps to ensure we reach all people at risk from NTDs.

These bacterial, viral and parasitic infections, which affect the health and economic futures of nearly 1.9 billion people across Latin America and the Caribbean, Africa and Asia, thrive in communities that lack access to health services, adequate sanitation and clean water. These infections can cause blindness, crippling physical disfigurements and increased susceptibility to HIV, exposing people to social stigma and discrimination. Without treatment, children face stunted growth and cognitive delays, posing a serious threat to their education. Moreover, there are approximately 44 million pregnant women infected with hookworms who are more likely to suffer from anemia and deliver low birthweight newborns – putting both mothers and babies at risk of mortality.

These detrimental health consequences have a spillover effect on the economic progress of families and communities, perpetuating the cycle of poverty. In short, these diseases are inextricably linked to maternal, newborn and child health; poverty; and inequality, requiring a comprehensive, holistic solution.

We enthusiastically welcome the G7's leadership on NTDs this year, which builds on the G7's longstanding commitments to tackle this problem, notably the historic Hashimoto Initiative, the first international parasitic disease control initiative, established during the 1998 Birmingham Summit. This paved the way for the G7's ongoing support for research and diagnostics, in addition to treatment and prevention efforts.

Major pharmaceutical companies have established a superb track record of leadership in the effort to control and eliminate NTDs, donating 2.5 billion treatments in 2012 and 2013 alone. Partners are working tirelessly to make sure that these treatments reach the people who need them, alongside over 70 endemic countries that have demonstrated ownership of this issue by developing dedicated, integrated plans to fight NTDs.

These are all steps in the right direction, however a \$220 million global annual funding gap for treatment continues to stand in the way of reaching the WHO 2020 targets. We urge the G7 to scale up investments now to ensure that

¹ The World Health Organization lists 17 neglected tropical diseases: Dengue, rabies, blinding trachoma, Buruli ulcer, endemic treponematoses (yaws), leprosy (Hansen disease), Chagas disease, human African trypanosomiasis (sleeping sickness), leishmaniasis, cysticercosis, dracunculiasis (guinea-worm disease), echinococcosis, foodborne trematode infections, lymphatic filariasis, onchocerciasis (river blindness), schistosomiasis (bilharziasis), soil-transmitted helminthiases (intestinal worms). The WHO recommends an integrated approach to overcoming the global impact of NTDs through five interventions: innovative and intensified disease management; preventive chemotherapy; vector ecology and management; veterinary public-health services; and the provision of safe water, sanitation and hygiene. Investing to Overcome the Global Impact of Neglected Tropical Diseases: third WHO Report on neglected tropical diseases, 2015.

programs are able to reach all affected populations, while also sustaining progress made thus far. Looking forward, the G7 and partners should ensure universal coverage against these diseases, an effort that will lead to measurable progress towards the elimination of extreme poverty; improved maternal and child health outcomes; and enhanced economic growth. Equally important, prioritizing NTDs will set the stage for success in achieving the proposed 2030 sustainable development goals.

To meet this need, the G7 should sustain current funding levels for neglected tropical disease control and elimination efforts, and implement a collective plan of action to fill the remaining gaps:

- Scale up access to existing treatments through mass drug administration and multisectoral approaches:
 Currently, just over 40 percent of people at risk of NTDs worldwide are being reached by treatment programs.
 Therefore, additional investment is essential to ensure coverage of those affected. G7 leaders can advance progress towards their 2008 Hokkaido Toyako commitment by reaching 75% of the people affected by NTDs through cost-effective, integrated approaches like mass drug administration a bundled packet of NTD treatments that can be delivered through community-based platforms, including schools. In addition, the G7 should invest in multisectoral approaches that integrate NTD control and elimination activities alongside efforts to improve maternal and child health, education, water, sanitation and hygiene, nutrition, reaching more people in need with a greater impact.
- Invest in new, innovative technologies and approaches: While we must continue to utilize these cost-effective, high-impact treatments, some NTDs require increased investment in new innovative technologies including drugs, diagnostics, vaccines and pesticides. One possible avenue for research and development support is through product development partnerships that can facilitate exchange of expertise and scientific knowledge to develop products for diseases that disproportionally affect the most vulnerable populations.

Yours respectfully,

Aeras

Africa Japan Forum (Tokyo, Japan)

Ms. Naoko Tsuyama, President

African Research Network for Neglected Tropical Diseases

Dr. Uche Amazigo

Former Director of the World Health Organization African Programme for Onchocerciasis Control Founder and CEO of the Pan-African Community Initiative on Education and Health

American Society of Tropical Medicine & Hygiene

Bayer HealthCare Pharmaceuticals

Michael Devoy, Global Medical Affairs & Pharmacovigilance

Brazilian Ministry of Health

Dr. Jarbas Barbosa, Secretary (Vice Minister) of Health Surveillance

cbm Canada

Mitchell Wilkie, Director, International Programs

cbm UK

Kirsty Smith, CEO

CBM-US

Caryl García, CEO

Children Without Worms

Dr. David Addiss, Director

Compassion Canada

Steve Clarke

DAHW German Leprosy and Tuberculosis Relief Association (Deutsche Lepra und Tuberkulosehilfe.e.V)

Sahayarani Antony

Department of Health, Philippines

Dr. Leda M. Hernandez Division Chief, Disease Prevention & Control Bureau

Deutsches Netzwerk gegen vernachlässigte Tropenkrankheiten (DNTDs)/German Network against Neglected Tropical Diseases

Die forschenden Pharma-Unternehmen in Deutschland / German Association of Research-based Pharmaceutical Companies

Harald Zimmer, Senior Manager International Affairs

Drugs for Neglected Diseases initiative

Dr. Bernard Pécoul, MD, MPH, Executive Director

DSW (Deutsche Stiftung Weltbevoelkerung)

Renate Baehr, Executive Director

Effect:hope (formerly The Leprosy Mission Canada)

Peter Derrick, Executive Director

Eisai Co., Ltd.

Sayoko Sasaki Vice President, Corporate Affairs Corporate Officer

Evidence Action

FIND

Fondation Mérieux

Catherine Dutel, General Secretary, Partnership for Dengue Control Benoît Miribel, Director General/ Directeur Général Christophe Longuet, Medical Director/ Directeur Médical

GlaxoSmithKline

Andy Wright, Vice President, Global Health Programmes

Global Health Innovative Technology Fund

Global Network for Neglected Tropical Diseases

Dr. Neeraj Mistry, Managing Director

Helen Keller International

Kathy Spahn, President and CEO

Health Partners International of Canada

Glen Shepherd, President

Dr. Adrian Hopkins

Chair of the Steering Group of the Global Alliance to Eliminate Lymphatic Filariasis Director of the Mectizan Donation Program

Imperial College London, Schistosomiasis Control Initiative

Prof. Alan Fenwick O.B.E., Director

Dr. Fiona Fleming, Director of Monitoring, Evaluation and Research

INMED Partnerships for Children

Dr. Linda Pfeiffer, Ph.D., President and CEO

Institut de recherche pour le développement (IRD-France)/Institute of Research for Development

Dr. Frédéric Simard, Head of Research Unit

MIVEGEC (Maladies Infectieuses et Vecteurs: Ecologie, Genetique, Evolution et Controle/Infectious Diseases and

Vectors: Ecology, Genetics, Evolution and Control)

Montpellier, France

Dr. Philippe Solano, Head of Research Unit

Intertryp (Interactions hôtes-vecteurs-parasites-environnement dans les maladies tropicales négligées dues aux trypanosomatidés/Host-vector-parasite interactions in neglected tropical diseases due to trypanosomatids) Montpellier, France

Institut Pasteur

Pr. Christian Bréchot, General Director

International Federation of Anti-Leprosy Associations

The International Society for Neglected Tropical Diseases

Marianne Comparet, Director

Kamran Rafiq, Communications Director

Japanese Organization for International Cooperation in Family Planning (JOICFP)

Johnson & Johnson

Bill Lin, Director, Worldwide Corporate Contributions

Kilimanjaro Centre for Community Ophthalmology International

Dr. Paul Courtright, Director

His Excellency John Kufuor

President of the Republic of Ghana (2001-2009)

Neglected Tropical Disease Special Envoy

The Leprosy Mission England and Wales

Peter Walker, National Director

The Leprosy Mission International

Geoff Warne, General Director

Liverpool School of Tropical Medicine

Professor Janet Hemingway, CBE, FRS Director, Liverpool School of Tropical Medicine

Liverpool School of Tropical Medicine

Professor David Molyneux

Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases

Professor Moses J. Bockarie, Director

The London Centre for Neglected Tropical Disease Research, The Natural History Museum London

Professor David Rollinson

Malaria Consortium

Mali, Ministry of Health, National Institute for Research in Public Health (INRSP)

Dr. Moussa Sacko

Medicines for Malaria Venture

Merck, known as MSD outside the United States and Canada

Ken Gustavsen, Executive Director, Corporate Responsibility

MITOSATH

Mundo Sano Foundation/Fundación Mundo Sano

Dr. Silvia Gold, President

Nagasaki University, Nagasaki Lymphatic Filariasis Centre

Dr. Kazuyo Ichimori

National School of Tropical Medicine, Baylor College of Medicine

Dr. Peter J. Hotez, Dean

Nigerian Institute of Medical Research

Dr. Margaret Mafe

Dr. James Orbinski OC, MSC, Bsc, MD, MA

Balsillie School of International Affairs

Organisation for the Prevention of Blindness / Organisation pour la Prévention de la Cécité (OPC)

Karim Bengraine

PATH

Steve Davis, President & CEO

Dr. Mirta Roses Periago

Former Director of the Pan American Health Organization Global Network for Neglected Tropical Disease Special Envoy

RESULTS Canada

Amy Bartlett, Executive Director

Sabin Foundation Europe

Michael W. Marine, Ambassador (Ret), CEO

Sabin Vaccine Institute

Michael W. Marine, Ambassador (Ret), CEO

The Salvation Army Canada & Bermuda Territory

Commissioner Susan McMillan, Territorial Commander

Save the Children

Sarah Bramley Caroline de Hilari Seung Lee

Sanofi

Dr. Robert Sebbag, Vice President "Access to Medicines"

Dr. Lorenzo Savioli, MD, DTM&H, MSC, Cav. O.M.R.I.

Former Director of the World Health Organization Department of Neglected Tropical Diseases

Shionogi & Co., Ltd.

Isao Teshirogi, Ph.D. President and CEO

Sightsavers

Dr. Caroline Harper

The Task Force for Global Health

Dr. Mark Rosenberg, President and CEO

TB Alliance

Willo Brock, Senior Vice President for External Affairs

Tokyo Women's Medical University

Dr. Hiroyoshi Endo, Professor and Chair, Department of International Affairs and Tropical Medicine

Ugoku/Ugokasu (Global Call to Action against Poverty Japan)

Masaki Inaba, Executive Director

University of British Columbia, Neglected Global Diseases Initiative

Richard Lester, Director

Jocelyn Conway, Coordinator

University Félix Houphouët Boigny, Abidjan Côte d'Ivoire

Professor Eliézer K. N'goran, Parasitologist, Head of Zoology and Animal Biology Department

University of Notre Dame, Haiti Program Neglected Tropical Diseases Initiative

Rev. Thomas Streit, C.S.C., Ph.D.

Founder and Principal Investigator

University of Notre Dame Eck Institute for Global Health

Sarah Craig, Communications Specialist

University of Toronto

James Maskalyk

Washington Global Health Alliance

Lisa Cohen, Executive Director

Washington University School of Medicine

Gary J. Weil, M.D. Professor of Medicine (Infectious Diseases)

WaterAid America

Lisa Schechtman, Director of Policy and Advocacy

WaterAid UK

World Food Programme

Peter Rodrigues, Head of the School. Feeding and Chronic Hunger Unit

World Vision Australia

Julianne Scenna, Director, Government & Multilaterals

World Vision International

Martha Newsome, Global Director, Health and Nutrition; Water, Sanitation and Hygiene (WASH)

Zambia NTD Control Technical Working Group and member of WHO-AFRO Regional Programme Review Group (NTD-RPRG (AFRO)

James Mwansa, Consultant

Dr André Yebakima

Medical Entomologist, PhD, Specialist of Vector Control

Winner of National Award for Scientific Research of Congo - Brazzaville (1981) Winner of Martinique Health Award (2015) Martinique (FWI)

Yonsei University College of Medicine, Institute of Tropical Medicine, Korea

Dr. Tai-Soon Yong